Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, has introduced a new treatment TALVEY® (talquetamab) for patients with relapsed and refractory multiple myeloma.
TALVEY® is a remarkable bispecific T-cell engaging antibody designed to target two crucial components: CD3 on T-cells and G protein-coupled receptor class C group 5 member D (GPRC5D) on the surface of multiple myeloma cells, as well as hard keratinised tissues. Importantly, GPRC5D exhibits minimal to no expression on B-cells and their precursors.
TALVEY® (talquetamab), is developed to address the specific needs of adult patients dealing with relapsed and refractory multiple myeloma (RRMM). These are individuals who have undergone at least three prior treatment regimens, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody, and have experienced disease progression during their most recent treatment.
As multiple myeloma advances and patients cycle through various therapies, the challenges of managing the disease become increasingly complex, and remission periods tend to shorten.
The introduction of talquetamab, which targets GPRC5D, has shown promising results in achieving deep responses. Unlike many other targets for multiple myeloma, GPRC5D's expression is predominantly limited to non-immune cells. This unique characteristic represents a significant breakthrough for the treatment of this heterogeneous disease.
Multiple myeloma is an incurable blood cancer that primarily affects a type of white blood cell called plasma cells, which are normally found in the bone marrow. In multiple myeloma, these malignant plasma cells undergo uncontrolled growth and transformation.
